Pagina 8 - I migliori oncologi di Oncologia - TOP-190 medici

Education

• Faculty of Medicine: Trakya University, 1982-1988
• Radiation Oncology Residency: Şişli Etfal Training and Research Hospital, 1994-1998
• Radiation Oncology Residency: Princess Margaret Hospital Toronto, 1996
• Phytotherapy Master's Degree: Istanbul University Faculty of Pharmacy, 2017-2018

Experience

• Professor, Head of Department: Health Sciences University Bursa Faculty of Medicine, Department of Radiation Oncology, 2021-2024
• Professor, Head of Department: Health Sciences University Izmir Faculty of Medicine, Department of Radiation Oncology, 2021-2024
• Professor: Department of Radiation Oncology, Health Sciences University Istanbul Hamidiye Faculty of Medicine, 2021-2024
• Lecturer Gelisim University SMYO, 2013-2020

Medical Interests

• Breast Cancer / Intraoperative Radiotherapy
• Gynaecological Cancers / Brachytherapy Applications
• Gastrointestinal System Tumours
• Prostate Cancer / Hydrogel Space Oar Certificate and Application
• Lung Cancers
• Brain Tumours
• Head and Neck Cancers

Dr. Hamdullah Sozen is a gynecologic oncologist with expertise in ovarian, endometrial, and cervical cancers. He is known for his skills in gynecological endoscopic surgery. Dr. Sozen uses minimally invasive techniques that help patients recover faster and improve outcomes.

He is an expert in colposcopy and cervical pathology. He has advanced training in both diagnostic and interventional procedures. Dr. Sozen completed his medical and oncology training at leading Turkish institutions, including Akdeniz University, Zeynep Kamil, and Istanbul Medical Faculty.

He is an active member of international associations such as ESGO and MEMAGO. Dr. Sozen has contributed to women’s cancer care through his clinical work, research, and teaching.

1. Medical Interests and Activities 
2. • Lung Cancer (Postdoctoral fellowship, MD Anderson Cancer Center, Houston, TX, USA)
3. • Interventional Bronchoscopy (Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA)
4.  
5. Education and Experience 
6. • Department of Thoracic Diseases, Liv Hospital, Ulus
7. • Faculty of Medicine, İstanbul Bilim University
8. • Ministry of Health Süreyyapaşa Thoracic Diseases Training and Research Hospital
9. • Faculty of Medicine, Marmara University Memberships
10. • IASLC (International Association for the Study of Lung Cancer)
11. • ACCP (American College of Chest Physicians)
12. • TAKD (Turkish Lung Cancer Society) (Executive Board Member)
13. • TTD (Turkish Thoracic Society)
14. • TÜSAD (Turkish Respiratory Research Society)
15.  
16. Memberships 
17. • IASLC (International Association for the Study of Lung Cancer) 
18. • ACCP (American College of Chest Physicians) 
19. • TAKD (Turkish Lung Cancer Society) (Executive Board Member) 
20. • TTD (Turkish Thoracic Society) 
21. • TÜSAD (Turkish Respiratory Research Society) 
22.  
23. Researches and Publications 
24. • International: 48 
25. • National: 60 
26. • Authorship for Books and Book Chapters at National Level: 4 
27. • Medical Fellowship, TEV Orhan Birman, MD 1998 
28. • “Fellow in American College of Chest Physicians” Title, 2009 

Medical Interests and Activities 

Interventional Radiology 

Oncological Radiology and Interventions 

Vascular Radiology 

Education and Experience 

Department of Radiology, Liv Hospital, Ulus (2012 -…) 

Interventional Radiology, İstanbul Faculty of Medicine (2006 - 2012) 

Faculty Hospital Hradec Kralove, Faculty of Medicine, Charles University (Observer, 2010) 

Interventional Radiology, Boston Children’s Hospital Vascular Anomaly Center, Harvard University (2008) 

Department of Radiodiagnostic, İstanbul Faculty of Medicine (2001 - 2005) 

Cerrahpaşa Faculty of Medicine

Memberships 

Turkish Society of Radiology 

Turkish Society of Interventional Radiology 

Cardiovascular and Interventional Radiologic Society of Europe 

European Society of Radiology

Researches and Publications 

National: 12

International: 23 

Presentations: 60

Medical Interests and Activities 

Hepatic Cirrhosis and Portal Hypertension 

Hepatic Cancer 

Viral Hepatitides (Chronic Hepatitis B, C and Delta Infections) 

Alcoholic Chronic Liver Disease 

Non-Alcoholic Fatty Liver Disease 

Stomach and Duodenal Ulcer 

Gastrointestinal Hemorrhage (Ulcer and Varicose Vein Bleeding) 

Functional Digestive System Disorders (Irritable Bowel Syndrome, Functional Intestinal Obstruction and Diarrhea...) 

Inflammatory Bowel Diseases (Ulcerative Colitis, Crohn’s Disease) 

Malabsorption Syndromes (Celiac Disease and Alike) 

Gastrointestinal Tract Malignancies

Education and Experience 

Liv Hospital, Ulus, Gastroenterohepatology Department (2013 ...) 

Associate Professor of Medicine, Obligatory Service at Gastroenterology, Şanlıurfa Training and Research Hospital (2010 - 2012) 

Subspecialty in Gastroenterohepatology, Department of Gastroenterohepatology, İstanbul Faculty of Medicine, İstanbul University (2004 - 2010) 

Research Fellow, Physician, Department of Internal Diseases, 

İstanbul Faculty of Medicine, İstanbul University (1992 - 1998)

Memberships 

Turkish Association For The Study of The Liver 

Turkish Society of Gastroenterology 

Inflammatory Bowel Disease Society 

Internal Diseases Specialty Association

Dr. Mustafa Aydın is an Internal Medicine specialist. He graduated from Gazi University Faculty of Medicine in 2009. He provides evidence-based care for adults, including diagnosis and treatment. He communicates in English.

His clinical focus includes chronic disease management, such as diabetes, hypertension, high cholesterol, and thyroid disorders. He treats gastrointestinal problems, including reflux, gastritis, ulcers, and liver diseases, and respiratory diseases like asthma and COPD. He manages infectious diseases. He provides preventive care with routine screenings, risk assessments, and personalized health plans.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Dr. Elnur Sahibov is a licensed Radiation Oncologist with 8 years of medical training and clinical experience. He completed his undergraduate and specialization studies at Marmara University Faculty of Medicine. From 2012 to 2016, he focused on advanced radiation oncology techniques.

Dr. Sahibov is known for his expertise in cancer treatment. He has helped improve patient outcomes and uses evidence-based protocols. He is accredited by leading medical institutions and is dedicated to ongoing professional development in oncology.

Dr. Merdan Fayda is a radiation oncologist with 19 years of experience in radio-oncology. He has studied at the Faculty of Medicine at the University of Istanbul and studied radiosurgery at the University of North Carolina (USA). He conducts 4D-radiotherapy, IMRT, MRI, CT, and PET-CT. He has participated in 16 international conferences, and is a member of 3 organizations.

Areas of Interests

• Pediatric Genitourinary Reconstrictive Surgery
• Hypospadias
• Circumssion
• Oncological Surgery
• Congenital Abnormalities of Upper and Lower Urinary System
• Newborn Surgery
• Pediatric Abdominal Surgery

Education
 

• 1997 -  19 Mayıs University
• 1998 National Pediatric Surgery Congress Best Reearch Study
• 2001-  Kocaeli University
• 2007 – Kosova Government
• 2009 – Yeditepe University
• 2009 – Suudi Arab be Congeress Best Clinical Study

Experience
 

• FMV Işık Highschool
• İstanbul University Cerrahpaşa Medical Faculty
• Ondokuz Mayıs University
• Zeynep Kamil Childrens Hospital
• Kocaeli University Medical Faculty
• UT Southwestern Medical Center Pediatric Urology, Dallas, USA
• Ege University Medical Center Pediatric Urology
• Yeditepe University

Prof. Dr. Selami Sozubir has authored 65 scientific publications, which have received over 11,000 reads and nearly 1,000 citations, reflecting his strong contribution to the field of pediatric surgery and urology.

Dr. Alper Karalok is a specialist in gynecology, obstetrics, and gynecologic oncology with over 18 years of experience. He is known for his skill in advanced surgical procedures such as myomectomy, hysterectomy, and ovarian cyst removal. He focuses on minimally invasive and robotic surgeries for gynecologic cancers.

Dr. Karalok graduated from Ankara University. He completed further training at Akdeniz University and Etlik Zübeyde Hanım Hospital. He also completed a fellowship at Memorial Sloan Kettering Cancer Center in the USA. He is a member of ESGO, ENYGO, and TRSGO, showing his dedication to professional growth in gynecologic oncology.

Associate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:

Breast Cancer

Prostate Cancer

Lung Cancer

Colorectal Cancer

Stomach Cancer

Ovarian Cancer

Prof. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.

His medical interests include:

Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)

Acute Leukemia

Chronic Leukemia Treatments

Hodgkin Lymphoma

Non-Hodgkin Lymphoma Treatments

Multiple Myeloma Treatments, MDS

Aplastic Anemia

ITP

TTP Treatments

Hypercoagulability

Hereditary Thrombophilia Treatments

Therapeutic Apheresis

Photopheresis

Geriatric Hematology Diseases.